Olmesartan Safety

No austere assurance issues were appear with olmesartan in analytic trials. The assurance almanac of olmesartan was agnate to placebo in seven randomized, double-blind, placebo-controlled appearance II and III trials that included 2,540 patients with hypertension. Adverse furnishings were appear in 42.2 percent and 42.7 percent of olmesartan-treated patients and placebo-treated patients, respectively. Olmesartan may could cause hypotension and astute renal abortion in patients who are sodium-or volume-depleted or whose renal perfusion is abased on the renin-angiotensin system. Like all ARBs, olmesartan may accelerate astute renal abortion in patients with renal avenue stenosis.

Significant hyperkalemia has not been appear with olmesartan, although it is possible, abnormally in patients with added accident factors for hyperkalemia. Of 3,825 patients advised with olmesartan during analytic trials, 5 appear angioedema.1 It is not accepted whether patients who accept developed angioedema with angiotensin-converting agitator (ACE) inhibitors or added ARBs accept an added accident of developing this ancillary aftereffect with olmesartan. No dosage adjustments are bare in earlier patients or in patients with abstinent to apparent hepatic or renal impairment. As with added ARBs, olmesartan is U.S. Food and Drug Administration class C during the aboriginal trimester of abundance and class D during the additional and third trimesters. In attenuate instances, angioedema and rhabdomyolysis from olmesartan accept been appear in postmarketing surveillance.